v3.26.3
Organization , Description of Business and Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Third-party Payers as a Percentage of Total
The Company’s total third-party payers and other customers in excess of 10% of total revenue and their related revenue as a percentage of total revenue were as follows:
 
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Medicare33 %33 %33 %33 %
UnitedHealthcare13 %14 %11 %14 %
46 %47 %44 %47 %
The Company's significant third-party payers in excess of 10% of total accounts receivable and their related accounts receivable balance as a percentage of total accounts receivable were as follows:
 
September 30, 2026December 31, 2025
Medicare19 %20 %
UnitedHealthcare15 %14 %
Schedule of Revenue Revenue included in biopharmaceutical and other revenue for the three and nine months ended September 30, 2026 and 2025 was as follows (in thousands of dollars):
Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Biopharmaceutical revenue$709 $646 $1,812 $5,573 
Contract manufacturing and testing— 169 — 3,129 
Total$709 $815 $1,812 $8,702